The Persistent Challenge of Developing Addiction Pharmacotherapies
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved..
There are currently effective Food and Drug Administration (FDA)-approved therapies for alcohol, nicotine, and opioid use disorders. This article will review the development of eight compounds used in the treatment of drug addiction with an emphasis on pharmacological mechanisms and the utility of preclinical animal models of addiction in therapeutic development. In contrast to these successes, animal research has identified a number of promising medications for the treatment of psychostimulant use disorder, none of which have proven to be clinically effective. A specific example of an apparently promising pharmacotherapeutic for cocaine that failed clinically will be examined to determine whether this truly represents a challenge to the predictive validity of current models of cocaine addiction. In addition, the development of promising cocaine use disorder therapeutics derived from animal research will be reviewed, with some discussion regarding how preclinical studies might be modified to better inform clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Cold Spring Harbor perspectives in medicine - 11(2021), 11 vom: 01. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Swinford-Jackson, Sarah E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 02.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1101/cshperspect.a040311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311791980 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311791980 | ||
| 003 | DE-627 | ||
| 005 | 20231226201612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/cshperspect.a040311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311791980 | ||
| 035 | |a (NLM)32601131 | ||
| 035 | |a (PII)a040311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Swinford-Jackson, Sarah E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Persistent Challenge of Developing Addiction Pharmacotherapies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved. | ||
| 520 | |a There are currently effective Food and Drug Administration (FDA)-approved therapies for alcohol, nicotine, and opioid use disorders. This article will review the development of eight compounds used in the treatment of drug addiction with an emphasis on pharmacological mechanisms and the utility of preclinical animal models of addiction in therapeutic development. In contrast to these successes, animal research has identified a number of promising medications for the treatment of psychostimulant use disorder, none of which have proven to be clinically effective. A specific example of an apparently promising pharmacotherapeutic for cocaine that failed clinically will be examined to determine whether this truly represents a challenge to the predictive validity of current models of cocaine addiction. In addition, the development of promising cocaine use disorder therapeutics derived from animal research will be reviewed, with some discussion regarding how preclinical studies might be modified to better inform clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Alcohol Deterrents |2 NLM | |
| 650 | 7 | |a Central Nervous System Stimulants |2 NLM | |
| 650 | 7 | |a Narcotic Antagonists |2 NLM | |
| 650 | 7 | |a Nicotinic Agonists |2 NLM | |
| 650 | 7 | |a Smoking Cessation Agents |2 NLM | |
| 650 | 7 | |a Bupropion |2 NLM | |
| 650 | 7 | |a 01ZG3TPX31 |2 NLM | |
| 650 | 7 | |a Naltrexone |2 NLM | |
| 650 | 7 | |a 5S6W795CQM |2 NLM | |
| 650 | 7 | |a Acamprosate |2 NLM | |
| 650 | 7 | |a N4K14YGM3J |2 NLM | |
| 650 | 7 | |a Varenicline |2 NLM | |
| 650 | 7 | |a W6HS99O8ZO |2 NLM | |
| 700 | 1 | |a O'Brien, Charles P |e verfasserin |4 aut | |
| 700 | 1 | |a Kenny, Paul J |e verfasserin |4 aut | |
| 700 | 1 | |a Vanderschuren, Louk J M J |e verfasserin |4 aut | |
| 700 | 1 | |a Unterwald, Ellen M |e verfasserin |4 aut | |
| 700 | 1 | |a Pierce, R Christopher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cold Spring Harbor perspectives in medicine |d 2012 |g 11(2021), 11 vom: 01. Nov. |w (DE-627)NLM21597185X |x 2157-1422 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:11 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/cshperspect.a040311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 11 |b 01 |c 11 | ||